UroGen Pharma (URGN) Competitors $4.19 +0.11 (+2.70%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$4.16 -0.04 (-0.84%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock URGN vs. GPCR, JANX, EVO, SPRY, ADPT, VERA, DYN, ANIP, BGM, and OCULShould you be buying UroGen Pharma stock or one of its competitors? The main competitors of UroGen Pharma include Structure Therapeutics (GPCR), Janux Therapeutics (JANX), Evotec (EVO), ARS Pharmaceuticals (SPRY), Adaptive Biotechnologies (ADPT), Vera Therapeutics (VERA), Dyne Therapeutics (DYN), ANI Pharmaceuticals (ANIP), Qilian International Holding Group (BGM), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry. UroGen Pharma vs. Structure Therapeutics Janux Therapeutics Evotec ARS Pharmaceuticals Adaptive Biotechnologies Vera Therapeutics Dyne Therapeutics ANI Pharmaceuticals Qilian International Holding Group Ocular Therapeutix UroGen Pharma (NASDAQ:URGN) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, media sentiment, dividends, profitability, valuation and risk. Does the MarketBeat Community believe in URGN or GPCR? UroGen Pharma received 346 more outperform votes than Structure Therapeutics when rated by MarketBeat users. However, 87.18% of users gave Structure Therapeutics an outperform vote while only 74.22% of users gave UroGen Pharma an outperform vote. CompanyUnderperformOutperformUroGen PharmaOutperform Votes38074.22% Underperform Votes13225.78% Structure TherapeuticsOutperform Votes3487.18% Underperform Votes512.82% Do analysts rate URGN or GPCR? UroGen Pharma presently has a consensus price target of $27.43, indicating a potential upside of 554.62%. Structure Therapeutics has a consensus price target of $79.86, indicating a potential upside of 225.28%. Given UroGen Pharma's higher probable upside, research analysts clearly believe UroGen Pharma is more favorable than Structure Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score UroGen Pharma 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, URGN or GPCR? Structure Therapeutics has lower revenue, but higher earnings than UroGen Pharma. Structure Therapeutics is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUroGen Pharma$91.87M2.10-$102.24M-$3.18-1.32Structure TherapeuticsN/AN/A-$89.62M-$0.87-28.22 Do institutionals & insiders believe in URGN or GPCR? 91.3% of UroGen Pharma shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 5.1% of UroGen Pharma shares are owned by company insiders. Comparatively, 9.4% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, URGN or GPCR? UroGen Pharma has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.69, meaning that its stock price is 269% less volatile than the S&P 500. Is URGN or GPCR more profitable? Structure Therapeutics has a net margin of 0.00% compared to UroGen Pharma's net margin of -129.11%. UroGen Pharma's return on equity of 0.00% beat Structure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets UroGen Pharma-129.11% N/A -47.94% Structure Therapeutics N/A -16.37%-15.68% Does the media favor URGN or GPCR? In the previous week, UroGen Pharma had 18 more articles in the media than Structure Therapeutics. MarketBeat recorded 24 mentions for UroGen Pharma and 6 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.10 beat UroGen Pharma's score of 0.09 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment UroGen Pharma 5 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral Structure Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryStructure Therapeutics beats UroGen Pharma on 10 of the 18 factors compared between the two stocks. Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart URGN vs. The Competition Export to ExcelMetricUroGen PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$193.19M$6.46B$5.34B$8.31BDividend YieldN/A2.63%5.27%4.11%P/E Ratio-1.338.4426.9619.60Price / Sales2.10258.50398.81136.05Price / CashN/A65.8538.3234.64Price / Book-1.516.416.774.50Net Income-$102.24M$143.95M$3.24B$248.60M7 Day Performance-42.68%0.24%0.26%-0.89%1 Month Performance-58.56%0.09%6.07%7.72%1 Year Performance-68.35%0.20%18.46%8.62% UroGen Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)URGNUroGen Pharma3.9864 of 5 stars$4.19+2.7%$27.43+554.6%-67.4%$193.19M$91.87M-1.33200Trending NewsAnalyst DowngradeAnalyst RevisionGap DownHigh Trading VolumeGPCRStructure Therapeutics2.1803 of 5 stars$25.00-0.7%$78.00+212.0%-35.9%$1.43BN/A-33.78136Positive NewsJANXJanux Therapeutics2.7531 of 5 stars$24.17-0.5%$95.25+294.1%-41.4%$1.43B$9.34M-20.6630Positive NewsEVOEvotec1.2885 of 5 stars$3.97-2.2%$5.93+49.5%-4.1%$1.41B$788.22M0.004,200Gap UpSPRYARS Pharmaceuticals2.3588 of 5 stars$14.26+4.9%$31.00+117.4%+70.2%$1.40B$89.15M-27.9690News CoverageAnalyst DowngradeInsider TradeADPTAdaptive Biotechnologies4.0903 of 5 stars$9.20+1.7%$9.83+6.9%+158.8%$1.40B$189.53M-8.44790Positive NewsGap DownVERAVera Therapeutics3.3716 of 5 stars$21.01-1.1%$63.33+201.4%-47.0%$1.35BN/A-8.0540Positive NewsDYNDyne Therapeutics3.4762 of 5 stars$11.66-1.4%$46.85+301.8%-62.6%$1.33BN/A-3.28100Positive NewsGap DownANIPANI Pharmaceuticals4.8286 of 5 stars$60.16+0.3%$80.13+33.2%-4.3%$1.31B$674.07M-109.38600Positive NewsBGMQilian International Holding GroupN/A$12.18-2.9%N/AN/A$1.22B$25.10M0.00298OCULOcular Therapeutix4.1194 of 5 stars$7.51+4.0%$16.25+116.4%+25.9%$1.20B$59.65M-5.69230Gap Up Related Companies and Tools Related Companies Structure Therapeutics Competitors Janux Therapeutics Competitors Evotec Competitors ARS Pharmaceuticals Competitors Adaptive Biotechnologies Competitors Vera Therapeutics Competitors Dyne Therapeutics Competitors ANI Pharmaceuticals Competitors Qilian International Holding Group Competitors Ocular Therapeutix Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:URGN) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | SponsoredMemorial Day Sale! Save 85% on Weiss Crypto Investor!President Trump just made his first big crypto move … Announcing the creation of a national strategic reser...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share UroGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
